rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

SiNtx Technologies, Inc.

SINT · Nasdaq

Health CareMedical DevicesNot moving yet

SINT stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 16.4% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 39
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$394K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
18 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$280KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months7
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Christopher Michael LyonsDirectorbought7,534at $2.902 Mar 2026filed 10 Mar 2026
Christopher Michael LyonsDirectorbought758at $2.9625 Feb 2026filed 10 Mar 2026
Jay M. MoyesDirectorbought1,000at $2.9123 Feb 2026filed 25 Feb 2026
Mark Lewis AndersonDirectorbought3,000at $3.0218 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders18-2 on the quarter
New · exited3 · 5
Reported value$2.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCnew · filed 14 Aug 2026627,615$558K+627,615
Bleichroeder LPnew · filed 13 Aug 2026523,013$978K+523,013
Veracity Capital LLCunchanged · filed 13 Jul 202676,674$143K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202631,930$60K+31,930
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202630,101$56K-2,043−6.4%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202623,531$44K00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202620,905$39K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202613,302$25K00.0%
UBS Group AGadded · filed 13 Aug 202611,921$22K+6,968+140.7%
Virtus Wealth Solutions LLCunchanged · filed 24 Jul 202610,000$19K00.0%
30 Jun 2024 – 30 Jun 2026
101621Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Robert Ryan Elmore Company insiderPresident · last 13 Apr 20260 · 0
Christopher Michael Lyons Company insiderDirector · last 2 Mar 20262 · 0
Jay M. Moyes Company insiderDirector · last 23 Feb 20262 · 0
Mark Lewis Anderson Company insiderDirector · last 18 Feb 20263 · 0
Eric K. Olson Company insiderChairman, President and CEO · last 6 Feb 20264 · 0
Gregg R. Honigblum Company insiderChief Investment Officer · last 6 Feb 20266 · 0
Kevin Trask Company insiderChief Financial Officer · last 6 Feb 20260 · 0
David W. Truetzel Company insiderDirector · last 29 Nov 20222 · 3
David Francis O'Brien Company insiderChief Operating Officer · last 27 Aug 20202 · 0
Bhajanjit Bal Company insiderCEO · last 28 Jul 20170 · 0
Bryan J. McEntire Company insiderChief Technology Officer · last 4 Jan 20160 · 0
Eric A. Stookey Company insiderDirector · last 4 Jan 20160 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202545.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-860%
Return on capital employedFY 2025 · to 31 Dec 2025-186%
Debt to equityFY 2025 · to 31 Dec 20250.00×
Research spendFY 2025 · to 31 Dec 2025451%
Share count trendFY 2025 · to 13 Mar 20263.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.1M
Free cash flowFY 2025 · to 31 Dec 2025−$8.8M

Analyst forecasts

No analyst forecasts yet.